Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study.
Procopio G, Chiuri VE, Giordano M, Alitto AR, Maisano R, Bordonaro R, Cinieri S, Rossetti S, De Placido S, Airoldi M, Galli L, Gasparro D, Ludovico GM, Guglielmini PF, Carella C, Nova P, Aglietta M, Schips L, Beccaglia P, Sciarra A, Livi L, Santini D; ABItude Study Group.
Procopio G, et al. Among authors: nova p.
ESMO Open. 2022 Apr;7(2):100431. doi: 10.1016/j.esmoop.2022.100431. Epub 2022 Apr 8.
ESMO Open. 2022.
PMID: 35405438
Free PMC article.